- Home
Documents
- Newly Diagnosed MM Patients Data Presented at ASH 2015
If you can't read please download the document
Newly Diagnosed MM Patients Data Presented at ASH 2015
Embed Size (px)
DESCRIPTION
All patients received Aspirin 325 mg/day VRd patients received HSV prophylaxis Durie B, ASH 2015 Abst 25 VRd Eight 21-day Cycles Rd Six 28-day Cycles Rd Maintenance Until PD, Toxicity or Withdrawal Lenalidomide 25 mg D Dex 40 mg D1, 8,15, 22 Randomization N = 525 Stratification: ISS (I, II, III) Intent to progression (yes/no) Bortezomib 1.3/mg 2 IV D 1, 4, 8, 11 Lenalidomide 25 mg/day D1-14 Dex 20 mg/day D1, 2, 4, 5, 8, 9, 11,12 Lenalidomide 25 mg/day D 1-21 Dexamethasone 40 mg D 1, 8, 15, 22 SWOG S0777 Bortezomib, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma SWOG S0777
